Garry V. Krepart
- Reproductive Medicine top 0.5%
- Ovarian cancer diagnosis and treatment 20
- Endometriosis Research and Treatment 3
- Obstetrics and Gynecology top 1%
- Endometrial and Cervical Cancer Treatments 11
- Uterine Myomas and Treatments 4
- Surgery top 10%
- Intraperitoneal and Appendiceal Malignancies 3
- Pathology and Forensic Medicine top 10%
- Lymphoma Diagnosis and Treatment 5
-
- Reproductive Biology and Fertility 4
-
- Cervical Cancer and HPV Research 2
Garry V. Krepart
30 papers receiving 1.0k citations
Peers
Comparison fields: 5 of 64
- Reproductive Medicine 798
- Obstetrics and Gynecology 518
- Surgery 421
- Pathology and Forensic Medicine 127
- Oncology 170
Countries citing papers authored by Garry V. Krepart
This map shows the geographic impact of Garry V. Krepart's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Garry V. Krepart with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Garry V. Krepart more than expected).
Fields of papers citing papers by Garry V. Krepart
This network shows the impact of papers produced by Garry V. Krepart. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Garry V. Krepart. The network helps show where Garry V. Krepart may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Garry V. Krepart, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2008 | 1 | |
| 2 | 2005 | 22 | |
| 3 | 2003 | 17 | |
| 4 | 2003 | 28 | |
| 5 | 2002 | 88 | |
| 6 | Antiestrogens affect both pathways of killer cell-mediated oncolysis. | 2000 | 7 |
| 7 | 1999 | 19 | |
| 8 | 1997 | 39 | |
| 9 | 1997 | 86 | |
| 10 | 1994 | 41 | |
| 11 | 1992 | 24 | |
| 12 | 1992 | 155 | |
| 13 | 1991 | 16 | |
| 14 | 1991 | 39 | |
| 15 | 1991 | 21 | |
| 16 | 1990 | 12 | |
| 17 | 1988 | 17 | |
| 18 | High-dose-intensity regimen of weekly doxorubicin and cisplatin in the treatment of patients with stage III and IV epithelial ovarian carcinoma. | 1987 | 3 |
| 19 | 1986 | 76 | |
| 20 | 1984 | 41 |
About Garry V. Krepart
Garry V. Krepart is a scholar working on Reproductive Medicine, Obstetrics and Gynecology and Pathology and Forensic Medicine, having authored 30 papers that have together received 1.1k indexed citations. Recurring topics across this work include Ovarian cancer diagnosis and treatment (20 papers), Endometrial and Cervical Cancer Treatments (11 papers), Lymphoma Diagnosis and Treatment (5 papers), Reproductive Biology and Fertility (4 papers), Uterine Myomas and Treatments (4 papers), Intraperitoneal and Appendiceal Malignancies (3 papers), Endometriosis Research and Treatment (3 papers) and Cervical Cancer and HPV Research (2 papers). The work is most often cited by research in Reproductive Medicine (798 citations), Obstetrics and Gynecology (518 citations) and Surgery (421 citations). Garry V. Krepart has collaborated with scholars based in Canada and United States. Frequent co-authors include Robert Lotocki, M. Heywood, J.F. Jeffrey, Jill Nation, Tung B. K. Le, Julian P. Smith, Felix N. Rutledge, Tien Le, Michael Helewa and Luis Delclos. Their work appears in journals such as Journal of Clinical Oncology, Cancer and American Journal of Obstetrics and Gynecology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.